Kyowa Hakko Kirin, Ultragenyx To Develop Treatment For X-linked Hypophosphatemia
This article was originally published in PharmAsia News
Kyowa Hakko Kirin is committed to expansion, and the deal with Ultragenyx for a first-in-class therapy of a rare bone disorder is small but establishes a clinical trial foothold overseas
You may also be interested in...
Ultragenyx already has a sales team in place to market its second commercial drug Crysvita (burosumab) – partnered with Kyowa Hakko Kirin – following its April 17 FDA approval for the treatment of pediatric and adult patients with x-linked hypophosphatemia (XLH).
Ultragenyx and partner Kyowa Hakko Kirin said burosumab (KRN23) met the primary endpoint regarding phosphate levels in a Phase III study that enrolled adult X-linked hypophosphatemia patients, but small effects on two out of three secondary endpoints could impact the product's use.
Pfizer’s partnership with the Alliance for Lupus Research to co-fund translational projects within the context of the pharma’s CTI program is a first. It’s a novel way to speed promising science into the clinic. But can Pfizer, a non-profit research foundation, and academic researchers reconcile their new roles and variant cultures to make the model work?